ID110521156

1. ID110521156 increases indirect bilirubin in humans.

   “A reversible, dose-dependent increase in indirect bilirubin resolved within 2 days after the last dose”

   Human trial28 days

   ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Indirect bilirubin

1. ID110521156 decreases mean daily glucose in humans.

   “CGM showed persistent reductions in mean daily glucose through 28 days.”

   Human trial28 days

   ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Mean daily glucose

1. ID110521156 decreases glucose exposure after OGTT in humans (-90.16, -102.44, and -124.69 mg·h/dL versus placebo -15.21 mg·h/dL).

   “Glucose exposure after OGTT (ΔAUGC0-4) decreased dose dependently (-90.16, -102.44, and -124.69 mg·h/dL for 50, 100, and 200 mg) versus placebo (-15.21 mg·h/dL).”

   Human trial28 days

   ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Glucose exposure after OGTT

1. ID110521156 decreases body weight in humans (-5.50, -6.89, and -9.88% versus placebo -3.1%).

   “After 28 days, dose-dependent reductions in body weight were observed (-5.50, -6.89, and -9.88% for 50, 100, and 200 mg) versus placebo (-3.1%).”

   Human trial28 days

   ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment

   ADA Scientific Sessions 2026 abstract·5 Jun 2026